Bolder BioTechnology, Inc. announced today that Dr. Joe Cox will give an oral presentation at the “A Poly-Pharmacy Approach to Mitigate Acute Radiation Syndrome (ARS)” meeting.
BOULDER, Colo., Oct. 24, 2018 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that Dr. Joe Cox, Company President, will give an oral presentation at the “A Poly-Pharmacy Approach to Mitigate Acute Radiation Syndrome (ARS)” meeting being held October 25, 2018 at the National Institute of Allergy and Infectious Diseases Conference Center, 5601 Fishers Lane, Rockville, Maryland. The title of Dr. Cox’s presentation is “Improving survival in a mouse H-ARS model using combinations of hematopoietic growth factors and an ACE inhibitor.” The meeting is being sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. Dr. Cox’s presentation will include results of animal studies using combinations of the company’s long-acting analogs of granulocyte-macrophage colony-stimulating factor (BBT-007), granulocyte- colony-stimulating factor (BBT-015), and interleukin-11 (BBT-059) to treat acute radiation syndrome. Each of these proteins has demonstrated the ability to increase survival and accelerate recovery of multiple blood cell types following exposure of animals to high doses of ionizing radiation. About Acute Radiation Syndrome (ARS) Government Support About Bolder BioTechnology
View original content:http://www.prnewswire.com/news-releases/bolder-biotechnology-to-present-preclinical-data-for-three-research-programs-at-acute-radiation-syndrome-meeting-300736680.html SOURCE Bolder BioTechnology, Inc. |